In Brief
Translocations of the MLL gene produce fusion proteins such as MLL-AF4 that cause poor-prognosis leukemias. Kerry et al. show that MLL-AF4 can spread into the gene body of some target genes. Spreading targets have an aberrant chromatin signature and are sensitive to DOT1L inhibitors.
INTRODUCTION
Translocations of the mixed-lineage leukemia (MLL) gene produce over 120 different MLL fusion proteins (MLL-FPs) that cause aggressive acute leukemias, the most common one being the MLL-AF4 fusion (Ballabio and Milne, 2012; Meyer et al., 2013) . Despite much progress in the treatment of childhood leukemias, infants carrying MLL rearrangements have a very poor prognosis (Pui et al., 2011) ; thus, improving therapies for MLL-FP patients remains an unmet need. Because MLL-FPs are considered to be the main drivers of leukemogenesis, their function regulating downstream target genes is key to understanding MLL-rearranged (MLLr) leukemias and for designing targeted therapies.
MLL-FPs retain several domains ( Figure 1A ) including a CXXC domain that binds specifically to unmethylated CpG (uCpG) DNA (Birke et al., 2002) , interaction sites with the multiple endocrine neoplasia type 1 (Menin) (Yokoyama et al., 2005) and lens epithelium-derived growth factor (LEDGF) proteins (Yokoyama and Cleary, 2008) , and an interaction with the polymerase-associated factor protein complex (PAFc) (Milne et al., 2010; Muntean et al., 2010) . Recruitment of MLL-FPs to gene targets is thought to be controlled by Menin, LEDGF, and PAFc interactions as well as CXXC binding to uCpGs (Milne et al., 2010; Muntean et al., 2010; Okuda et al., 2014; Yokoyama and Cleary, 2008; Yokoyama et al., 2005) . Supporting this, a minimal MLL-FP containing just the PWWP domain of LEDGF, the CXXC domain of MLL, and the transactivation domain of the fusion partner can transform bone marrow progenitors and recapitulate MLL-FP binding at a few select genes (Okuda et al., 2014) . However, a minimal CXXC domain can be recruited to the HoxA9 locus in the absence of a Menin/LEDGF interaction (Milne et al., 2010) , although others have suggested that the CXXC domain has no role in recruitment and instead protects uCpG sites from methylation (Risner et al., 2013) . Recent data also suggest that Menin is unimportant for wild-type MLL (Borkin et al., 2015; Li et al., 2013) , whereas LEDGF is required for MLL but not MLL-FP recruitment (Zhu et al., 2016) . Thus, it still remains an open question exactly how MLL-FPs are recruited to particular gene targets.
MLL-FP recruitment is associated with increased histone 3 lysine 79 di-and tri-methylation (H3K79Me2/3) at target genes, an epigenetic mark associated with gene activation (Bernt Guenther et al., 2008; Krivtsov et al., 2008; Milne et al., 2005) . H3K79Me2/3 levels are controlled by the disruptor of telomeric silencing 1-like (DOT1L) protein (Jones et al., 2008) . In MLL-FP leukemias, DOT1L directly interacts with AF9 or ENL (Biswas et al., 2011; Mueller et al., 2007) , and can be mis-targeted to MLL-FP-bound genes where it is associated with inappropriate activation of gene expression (Milne et al., 2005) (Figure 1B) . A recent study analyzing MLL-ENL binding suggests that there are two distinct classes of binding: proximal (5 0 ) or distal (3 0 ) to the transcription start site, with proximal binding being particularly sensitive to DOT1L inhibition (Garcia-Cuellar et al., 2016) . MLL-AF4 can also bind in broad regions of up to 100 kb that correlate with large domains of H3K4me3 (Guenther et al., 2008) and MLL-AF9 transformed mouse bone marrow cells display H3K79me2 peaks with a similar wide spatial distribution (Bernt et al., 2011) . Despite all this work, there is no current consensus on whether the main activity of MLL-FPs is the recruitment of DOT1L or whether different binding patterns of MLL-FPs are associated with distinct functional outcomes.
Here, we reveal a strong co-dependent relationship between MLL-AF4 and Menin binding at a small number of target genes containing uCpGs. At a subset of these gene targets, we observe MLL-AF4 and Menin spreading that is bookended by uCpGs. These spreading targets are distinct from super-enhancers, are associated with high levels of gene transcription, have an aberrant H3K79me2/H3K36me3 signature, and are predictive of a poor overall survival in patients with acute lymphoblastic leukemia (ALL). These gene targets also display a remarkable dependence on H3K79me2 and the fusion protein for their sustained expression in leukemia. Together, this work shows that MLL-FP spreading occurs at genes important in MLL leukemogenesis and has the potential to act as a biomarker for therapeutic response.
RESULTS

MLL-AF4 Binds Exclusively to a Subset of uCpGs
Using MLL(N) and AF4(C) chromatin immunoprecipitation sequencing (ChIP-seq) in the human MLL-AF4 SEM cell line (Figure 1C) , we identified 4,427 peaks and a gene set of 2,597 unique genes (Table S1 ). MLL(N) ChIP-seq replicates had 81% peaks in common ( Figure 1D ), which identified 96.4% promoter-bound MLL(N) gene targets from our original ChIP-seq dataset (Table  S1 , ''Overlaps''). This gave us high confidence in the reproducibility of our gene target identification. To test the specificity of the MLL-AF4 target set, we performed MLL-AF4 small interfering RNA (siRNA) knockdowns coupled with nascent RNA sequencing (RNA-seq) ( Figure S1A ) and MLL-AF4 ChIP-seq (Figure S1B) . Our MLL-AF4 gene target set was significantly downregulated at most genes ( Figure S1A , p < 0.01, Mann-Whitney U test) and lost MLL-AF4 ChIP-seq signal at 85% of target gene promoters (Figures S1B and S1C) . Among the 15% of MLL-AF4 gene targets with no reduced ChIP-seq signal, one-third showed a significant change in gene expression following MLL-AF4 knockdown ( Figure S1C ). This suggests that these targets are also directly regulated by MLL-AF4, even though they consist primarily of promoters with a low MLL(N) ChIP-seq signal ( Figure S1D) .
If the CXXC domain is essential for MLL-AF4 recruitment, we would expect all MLL-AF4 binding sites to occur at regions of uCpGs. To test this, we used a biotinylated CXXC affinity purification (Bio-CAP) assay for high-sensitivity detection of regions of uCpG dinucleotides in SEM cells, combined with an assay for transposase-accessible chromatin sequencing (ATAC-seq) (Buenrostro et al., 2013) to identify regions of open chromatin ( Figure 1C ). Similar to results using non-methylated CpG/methylated-CpG island recovery assay sequencing (CIRA/MIRA-seq) with MLL-AF6 (Okuda et al., 2014) , all MLL-AF4 binding occurred at open uCpG regions (Figure 1E) with the highest uCpG enrichment occurring at the center of MLL-AF4 binding sites ( Figure S1E ). However, MLL-AF4 binding occurred at only 20% of uCpG sites ( Figure 1F ), indicating that open uCpG sites alone are not sufficient for MLL-AF4 recruitment. The Venn diagram ( Figure 1F ) shows a few MLL-AF4 sites that do not overlap with uCpGs, but it is clear from the heatmap that all MLL-AF4 binding sites occur at uCpG sites. The discrepancy is likely due to the reduced sensitivity of peak-calling programs used for the Venn diagram analysis.
To determine whether other CXXC domain-containing proteins (''CXXC proteins'' from now on) are also restricted to only a proportion of uCpG sites, we performed ChIP-seq for CFP1 (a CXXC protein member of the SET1 complex associated with gene activation), and KDM2B (a CXXC protein involved in the recruitment of the polycomb group repressive complex [PRC] [Farcas et al., 2012] ), in SEM cells ( Figure 1C) . In contrast to MLL-AF4, CFP1 and KDM2B bound more ubiquitously to uCpG sites, being found at 50% and 89% of all uCpG sites, respectively ( Figure S1F ). Because the CXXC domains of MLL-AF4, CFP1, and KDM2B are highly related (Long et al., See also Figure S1 .
484 Cell Reports 18, 482-495, January 10, 2017 2013), the differences in the number of bound uCpGs may be due to other protein interactions influencing recruitment.
Genome-wide Recruitment of Menin Mirrors that of MLL-AF4
To investigate whether MLL-AF4-specific interactions contribute to uCpG binding, we analyzed two complexes thought to be involved in MLL-FP recruitment: Menin/LEDGF and PAFc (Figures 1A-1C ). Except for a very few Menin binding sites (Figure 1G , very bottom of heatmap), we found that almost all MLL-AF4 binding sites overlap with detectable Menin binding ( Figure 1G ). Many MLL-AF4 binding sites had only low levels of detectable Menin ( Figure 1G ), and thus strict peak-calling parameters produce an MLL-AF4/Menin overlap at only a subset of binding sites ( Figure 1H ). However, when MLL-AF4 binding sites were separated into either high or low Menin binding, we saw a direct relationship between levels of Menin binding and levels of MLL-AF4 binding ( Figure S1G ). Furthermore, a direct comparison of MLL(N) and Menin ChIP-seq reads at MLL-AF4 binding sites showed a significantly strong positive correlation (r 2 = 0.96) ( Figure 1I ), whereas neither KDM2B nor CFP1 binding correlated with Menin ( Figures 1J and S1H ). Thus, an association with Menin represents a feature that may serve to restrict MLL-AF4 recruitment to a particular subset of uCpG sites. ChIP-seq on two members of PAFc, PAF1 and LEO1 (Figure 1C) , overlapped with less than one-half of MLL-AF4 binding sites, and 4,892 (78%) of PAFc binding sites had no MLL-AF4 binding ( Figure S1I ). Thus, compared to Menin binding, there is very little evidence for an MLL-AF4:PAF1 association genomewide ( Figure 1H ), but it is possible that PAFc is necessary for recruitment only at select sites.
The Menin:MLL-AF4 Interaction Is Sufficient for Recruitment To directly test the functionality of the interactions between Menin, MLL-AF4, and potentially PAFc, we used a Tet-repressor (TetR) system (see Figure 2A legend) previously designed to investigate the recruitment of PRC proteins (Blackledge et al., 2014) . Using ChIP-qPCR, we detected binding of Menin but not PAF1 in the presence of TetR-MLL-AF4 but not the TetR-only control (Figure 2B , left versus right panel), and recruitment was lost upon treatment with doxycycline ( Figure 2B , left panel, red line). Reciprocal experiments using TetR-Menin-and TetR-PAF1-expressing mESC lines transiently transfected with MLL-AF4 produced equivalent results (Figures S2A and S2B) . Despite being able to recruit other members of PAFc, TetR-PAF1 was not sufficient to recruit MLL-AF4 ( Figures S2B and S2C ). Expression of different constructs was confirmed with either western blot or qPCR (Figures S2D and S2E) . It has been recently shown that knockdowns of LEDGF sometimes lead to an increase in MLL-FP binding (Zhu et al., 2016) . Similar to Zhu et al., we noticed a slight increase in MLL(N) ChIP at TetO in the presence of Ledgf siRNA ( Figures  S2F and S2G ), although we were only able to achieve a 30% Ledgf knockdown at the RNA level ( Figure S2F ).
Our results so far support previous models suggesting that Menin recruits MLL-FPs (Yokoyama et al., 2005 , and contrasts with previous reports that suggest that PAFc can recruit MLL-FPs (Milne et al., 2010 ; Muntean et al., 2010) ( Figure 2C ).
The TetR assay does not establish directionality of these interactions; thus, it is also possible that MLL-FPs can recruit Menin (Caslini et al., 2007) , or that the two proteins co-stabilize each other, as has recently been suggested for LEDGF and wild-type MLL (Zhu et al., 2016) . In addition, it is possible that a relatively weak MLL-AF4:PAFc interaction is stabilized by other interactions when it occurs at active genes. To explore these issues further, we performed MLL-AF4, PAF1, or Menin siRNA knockdowns in SEM cells (Figures 2D-2H ). MLL-AF4 knockdowns have a strong effect on the binding of Menin to gene targets (Figure 2Gi ) and a moderate but detectable effect on PAF1 binding (Figure 2Hi ). Menin knockdowns reduce both MLL-AF4 and PAF1 binding to gene targets ( Figures 2E-2Hii ), whereas two different PAF1 siRNAs produce a similar result in that they reduce Menin binding slightly but have little effect on MLL-AF4 except at the HOXA9 locus ( Figures 2E-2Hiii and S2H ). Together, these data show that there is a complex co-recruitment relationship between MLL-AF4 and Menin, and that PAF1 does not have a major role in recruiting MLL-AF4 to most gene targets. However, MLL-AF4 either directly or indirectly, has a role in maintaining stable PAF1 binding at specific gene targets. To analyze MLL-AF4 function in further detail, we next tried to determine whether MLL-AF4 displayed distinct binding profiles at different subsets of genes.
Spreading of MLL-AF4 Marks a Subset of Highly Expressed Genes
An analysis of MLL-AF4 binding profiles revealed two patterns of binding. The majority of MLL-AF4 binding sites displayed narrow binding at the promoter and a normal pattern of H3K79me2 and H3K36me3 ( Figure 3A) . We also occasionally observed MLL-AF4 spreading greater than 4 kb into the gene body without exceeding the end of the gene, and this was associated with H3K79me2 spreading and a reduction or loss of H3K36me3 throughout the gene body ( Figure 3B ). Spreading was observed at 149 (3.4%) MLL-AF4 gene target isoforms (117 unique gene targets) in SEM cells ( Figure S3A ; Table S2 ). A Gene Ontology analysis revealed that spreading occurred at genes involved in hematopoiesis as well as lymphocyte activation and differentiation, showing that it could have a role in leukemia initiation or maintenance ( Figure S3B ). We confirmed that spreading was specific to MLL-AF4 using MLL-AF4 siRNA knockdowns followed by ChIP-qPCR in regions of spreading at specific targets ( Figure S3C ). Spreading is reminiscent of broad MLL-AF4 binding domains at sites of broad H3K4me3 (Guenther et al., 2008 ), although we found that there was less than a 50% overlap between our spreading dataset and the MLL-AF4 target set originally identified by Guenther et al. (Figure S3D ).
To test whether MLL-AF4 spreading was a marker of significant functional activity, we analyzed nascent RNA-seq data and found that spreading MLL-AF4 targets showed significantly higher expression compared to targets of non-spreading MLL-AF4, or active gene targets bound by CFP1 (p < 0.0001, two-tailed Mann-Whitney U test; Figure 3C ). Spreading targets were also highly enriched for H3K79me2 at the 5 0 end of the gene compared to non-spreading MLL-AF4 or non-MLL-AF4 targets ( Figure 3D .7
Menin Menin Figure S2H ) experiments as these were performed in parallel. Error bars represent the SD of at least three biological replicates. See also Figure S2 .
that the H3K79me2 pattern observed is a consequence of spreading MLL-AF4. Because broad MLL-FP binding domains have been observed previously (Bernt et al., 2011; Guenther et al., 2008) , one possibility is that spreading identifies bona fide MLL-AF4 target genes, whereas non-spreading peaks represent wildtype MLL and AF4 co-bound sites. To test this, we separated the MLL-AF4 siRNA nascent RNA-seq and ChIP-seq datasets (Figures S1A-S1D) into spreading and non-spreading target sets. We found that almost all spreading and non-spreading targets are bound by MLL-AF4, but spreading targets are more likely to be downregulated by a loss of MLL-AF4 (Figures S3E and S3F) . A recently generated FLAG tagged MLL-Af4 ChIPseq experiment in CD34
+ cord blood cells ( MEIS1  ATP8B4  RUNX2  KLRK1  CPEB2  FUT4  MBNL1  FLT3  PAN3  SPN  SUPT3H  LRMP  CDK6  CAMK2D  TBC1D14  CXXC5  DGKD  PPP2R5C  MAFG  PDE4DIP  ELOVL6  PTPN6  SEMA3A  LMO4  DIAPH1  ADAM10  ZCCHC7  CACNB4  PLEK  ANP32A  LRRFIP2  RUNX1  BCL11A  JMJD1C  NUSAP1  MEF2C  CXorf21  IER2  BCL2  SOX11  HMGB1  CHD2  SYK  CTBP2  SYT1  NR3C1  TRHDE  ARID1B  STK17B  ARHGDIB  EVI2B  PTPRR  ROBO1  SPRY4  ZCCHC6  TGFBR2  GNAQ  PTEN  STC2  PAX5  PIK3CD  ARID2  SENP6  RHOH  IGF1R  HIVEP2  LEF1  ERG  ERG  ZC3HAV1  TPD52  ARRDC3   MEIS1  PROM1  RUNX2  ATP8B4  FLT3  ZC3H12C  CPEB2  KLRK1  CLECL1  FUT4  CAMK2D  MBNL1  CLEC2D  ZCCHC7  JMJD1C  SUPT3H  CDK6  APOLD1  REEP3  RNF220  CDCA7  UBASH3B  PDE4DIP  HMGA2  ADAM10  PAN3  BCL11A  CXXC5  TBC1D14  LRMP  PPP2R5C  PTPN6  SENP6  TAPT1  IKZF1  SYT1  MEF2C  ELOVL6  NR3C1  CACNB4  STK17B  RUNX1  ZMYND8  LMO4  BCL2  IGF1R  ZEB2  RNF19B  AFF1  ARID2  PTPRR  PLEK  SYK  MAFG  LAT2  GNAQ  LRRFIP2  MAP3K1  EVI2B  CHD2  DIAPH1  CYTIP  TGFBR2  DGKD  ZCCHC6  CXorf21  ST8SIA4  SPEN  HMGB1  LEF1  SEMA3A  TSC22D2  PTEN  STC2  ARHGDIB  TMPO  SMC4  ARID1B  HIPK3  ANP32A  SNHG3  SPRY4  IER2  TNRC18  PIK3CD  CLEC2B  PAX5  HIVEP2  HNRNPF  RHOH  TGIF1  NUSAP1  ARRDC3  TRHDE  ROBO1  SOX11  EBF1  ZC3HAV1 TPD52 ERG lowed us to unambiguously identify MLL-Af4 binding sites in a primary transformed cell. FLAG-MLL-Af4 ChIP-seq identified almost 3,000 MLL-Af4 gene targets, similar to the number we obtained in SEM cells (Lin et al., 2016) . FLAG-MLL-Af4 binding could be divided into both spreading and non-spreading targets, about 40%-50% of which overlapped with MLL-AF4 targets in SEM cells ( Figures S3G-S3I ). Taken together, this suggests that MLL-AF4 can display both spreading and non-spreading binding patterns, but spreading gene targets are less common and are more significantly associated with a dependence on MLL-AF4 for their activation.
In order to better understand the significance of our spreading target set, we analyzed the expression profile of SEM spreading targets in two different patient cohorts and found that 64%-79% of SEM spreading targets are overexpressed in MLLr ALL patients ( Figures 3E and 3F ). Using a super-PC analysis (Bair and Tibshirani, 2004) , we also found that there is a signature within the spreading target set that is predictive of a poor prognosis in patients (Figures 3G and 3H) . Thus, MLL-AF4 spreading targets also have clinical significance in patients.
Spreading Is Common among MLL Fusion Proteins but Not Wild-Type MLL
Because spreading is an important feature of MLL-AF4 binding, we investigated how common spreading is for other MLL-FPs. MLL(N) ChIP-seq in the MLL-AF6 cell line ML-2 detects the fusion protein unambiguously due to a deletion of the wild-type MLL allele. Spreading for MLL-AF6 was observed at 47 (43.1%) gene target isoforms ( Figure 4A ; Table S3 ), and similar to MLL-AF4, these spreading targets displayed a significant increase in H3K79Me2 compared to non-spreading MLL-AF6 targets (Figure 4B ). The high percentage of spreading peaks within the MLL-AF6 set is due to the low number (109) Tables S1 and S4 ). High expression of ARID2, JMJD1C, MBNL1, MEF2C, or RUNX2 alone is associated with at least one indicator of poor prognosis in ALL patients (Table S4) , and CPEB2, MBNL1, RUNX2, and ZEB2 are all specifically overexpressed in MLL-FP leukemias (Figures 4H  and S5A; Table S5 ). Interestingly, RUNX2, MBNL1, JMJD1C, SENP6, MEF2C, and ZEB2 are also hypomethylated in MLL-FP samples compared to either normal cells or other leukemias (Figure S5B ; not shown). Although these data show that some MLL-FP spreading targets can individually have an important role in human leukemias, there does not seem to be a single key set of spreading targets that are necessarily found in all MLL-FP samples. However, taken in total, the data show that MLL-FP spreading is an indicator of particularly significant MLL-FP activity.
Spreading Correlates with Menin and MLL-AF4 Complex Components
To better understand MLL-FP spreading, we analyzed whether spreading is related to other MLL-AF4 complex components ( Figure 5A ). When all MLL-AF4 spreading targets were sorted by length, the ChIP-seq signal of MLL(N) and AF4(C) generated a characteristic curve shape ( Figure 5B , panels 1 and 2). Interestingly, MLL-AF4 spreading is punctuated by uCpG sites, with the beginning and end of spreading domains demarcated by uCpG sites ( Figures 5A and 5B, panel 3 ). This indicates a role for the CXXC domain in stabilizing spreading and agrees with the hypomethylation observed at spreading MLL-AF4 targets in patients ( Figure S5B ). This is an important role for the CXXC domain within the context of MLL-AF4 because neither KDM2B nor CFP1 showed the same spreading pattern, even though they both bind to uCpGs ( Figures 5A and S6A ). The majority of uCpG regions under spreading peaks were within 1-2 kb of each other and rarely exceeded 4 kb, with 7 kb being the greatest distance observed ( Figure S6B) . Therefore, the proximity of uCpG sites to each other under the spreading peaks appears to be important and may be a limiting factor in determining the degree of spreading. If true, this also suggests that spreading may be non-random, and only genes with a clustered uCpG landscape downstream of their promoter are amenable to spreading.
Spreading was not simply a result of an association with basal transcription factors because neither RNAPII nor members of PAFc showed the same spreading pattern; instead, they extended beyond the spreading domain to the end of the gene ( Figures 1C, 5A , and S6C). Conversely, both Menin and ENL displayed identical spreading patterns to MLL-AF4 ( Figures 1C, 5A and 5B, panels 4 and 5). Our observation that Menin knockdowns reduce MLL-AF4 binding at spreading gene targets (Figures 2E-2G ) supports the idea that there is a role for Menin in stabilizing spreading. In conclusion, we envisage a model whereby CXXC-mediated weak binding of the fusion protein at low-CG density uCpG sites in the gene body can be stabilized by CXXC-mediated recruitment to the CG-rich uCpGs at promoters ( Figure 5C ). However, this depends on the weak binding sites occurring in close proximity to the promoter and each other, with Menin or ENL facilitating stabilization through a bridging mechanism ( Figure 5C ).
Spreading MLL-AF4 Represents a Subset of Broad H3K4me3 Distinct from Super-Enhancers
Several recent studies have characterized broad binding chromatin domains as markers of functional significance, including super-enhancers (Lové n et al., 2013; Whyte et al., 2013) and broad regions of H3K4me3 (Benayoun et al., 2014) . Whereas genes associated with super-enhancers were shown to correlate with increased expression, genes marked by broad H3K4me3 showed an increase in transcriptional consistency, i.e., less variation in transcription rate between replicates as determined by RNA-seq and nascent RNA-seq, as well as an increase in gene expression (Benayoun et al., 2014) . Here, we wanted to determine whether MLL-AF4 spreading domains were related to either super-enhancers or broad H3K4me3 peaks.
First, we characterized super-enhancers and broad H3K4me3 domains in SEM cells using the same criteria as the original studies ( Figures S6D-S6G ). Almost all regions of spreading MLL-AF4 were distinct from super-enhancers, but the majority (87%) of spreading MLL-AF4 gene targets were a subset of 
. MLL-FP Spreading Occurs in Multiple in MLL Leukemias
(A) Spreading MLL-AF6 peaks were defined as peaks that extend greater than 4 kb from the TSS into the gene body without going beyond the end of the gene. Using these criteria, 47 spreading MLL-AF6 peaks were identified in ML-2 cells (Table S2) .
(legend continued on next page)
Cell Reports 18, 482-495, January 10, 2017 489 broad H3K4me3 gene targets ( Figure 5D ). Despite being distinct from super-enhancers, spreading MLL-AF4 correlated with MED1 and BRD4 binding as well as H3K27Ac ( Figure 5E , panels 1-3). The major difference between MLL-AF4 spreading domains and super-enhancers was the lack of H3K4me1 enrichment; instead, spreading overlaps with H3K4me3 and H3K79me2 ( Figure 5E , panels 4-6). Similar to past work (Benayoun et al., 2014) , gene targets of the 5% broadest H3K4me3 peaks in SEM cells showed a significant increase in transcriptional consistency compared to genes marked by the remaining 95% of H3K4me3 peaks (p < 0.0001, Mann-Whitney U test, Figure S6H ). As a whole, gene targets of MLL-AF4 showed a significant increase in transcriptional consistency compared to H3K4me3-marked genes (p < 0.0001, MannWhitney U test; Figure S6I ), suggesting that maintaining gene regulation within narrow limits could be an important property of MLL-AF4 controlled gene expression crucial for the leukemia. However, spreading MLL-AF4 gene targets did not show increased transcriptional consistency compared to all MLL-AF4 gene targets ( Figure S6I ); thus, this was not a feature specific to spreading. Based on the signature of histone marks and protein associations, spreading MLL-AF4 represents a hybrid of broad H3K4me3 domains and super-enhancers, with transcriptional properties such as high expression ( Figure 3C ) more similar to super-enhancers.
Gene Targets of Spreading MLL-AF4 Display Increased Sensitivity to DOT1L Inhibition
If it is possible to target spreading MLL-AF4 target genes, it is likely that this would have a strong and specific effect on the inhibition of leukemia maintenance. Because spreading MLL-AF4 targets are marked with high levels of H3K79me2 ( Figure 3D ), we wanted to determine whether they are particularly sensitive to the DOT1L inhibitor EPZ-5676 (Daigle et al., 2013) . Treatment of SEM cells with 2 mM EPZ-5676 for 7 days produced an almost complete loss of the H3K79me3 mark for all genes tested (Figure S7A) . Using nascent RNA-seq, we identified 2,462 downregulated genes, 84% of which were marked by H3K79me2 (Figure 6A ) and that included a number of spreading targets (e.g., CDK6; Figure 6B ). As a group, over 50% of spreading targets were downregulated following EPZ-5676 treatment compared to only 16% of non-spreading MLL-AF4 targets and 23% of H3K79me2-marked genes (p < 0.0001, two-tailed Fisher's exact test; Figure 6C ). Furthermore, spreading MLL-AF4 targets were among those that showed the greatest downregulation, even compared to genes that had similar levels of high expression (Figure 6D) . Spreading MLL-AF4 gene targets were also significantly more downregulated in response to EPZ-5676 compared to nonspreading MLL-AF4 gene targets (p < 0.0001, Mann-Whitney U test; Figure 6E ). Therefore, spreading MLL-AF4 targets are among the most sensitive to treatment with EPZ-5676 when compared to all other genes. Using a randomly selected group of genes with levels of H3K79me2 similar to those of spreading MLL-AF4 targets ( Figure S7B ), we also found that spreading MLL-AF4 targets were significantly more downregulated after EPZ-5676 treatment ( Figure S7C , top and bottom; p < 0.0001 and p < 0.01, respectively; Mann-Whitney U test). Therefore, genes marked by spreading MLL-AF4 show increased sensitivity to EPZ-5676 through a mechanism not simply determined by high levels of H3K79me2. Interestingly, spreading targets that overlapped with either broad H3K4me3 or super-enhancers were significantly more sensitive to DOT1L inhibition than spreading MLL-AF4 targets alone ( Figure S7D ). This indicates that there are further subdivisions of activity within spreading targets themselves, something that may explain recent results looking at DOT1L and BRD4 cooperation (Gilan et al., 2016) .
As well as being particularly sensitive to a loss of H3K79me2/3, spreading MLL-AF4 gene targets were significantly downregulated compared to non-spreading and non-MLL-AF4 targets by MLL-AF4 siRNA treatment (p < 0.0001, two-tailed Mann Whitney U test; Figure 6F ). Therefore, the increased gene expression observed at MLL-AF4 spreading targets is significantly linked to both MLL-AF4 and H3K79me2 and is more likely to be downregulated by DOT1L inhibition.
Sensitivity of Spreading Gene Targets Provides a
Rationale for Combination Therapy Using DOT1L Inhibitors It seems unlikely that a single drug alone will be effective in treating MLL-AF4 leukemias. Even among MLL-AF4 spreading targets, some gene targets have an increased sensitivity to a loss of H3K79me2 (Figures 7A and 7B ; Table S6 ). We recently showed that the BCL-2-specific protein inhibitor ABT-199 synergizes with DOT1L inhibitors (Benito et al., 2015) , potentially because BCL-2 protein levels are not strongly affected by DOT1L inhibitor concentrations that affect more sensitive targets such as CDK6 or BCL11A ( Figure 7B ). Because Menin is partly responsible for spreading (see Figures 2E-2G and 5A-5C), the Table S5 . See also Figures S4 and S5 .
use of Menin inhibitors represents another way to target sensitive MLL-AF4 spreading genes (see Figure S7E) . In an extension of our earlier work, we find that there is a strong synergy between ABT-199 and the DOT1L inhibitors EPZ5676 and SGC0946, as well as a strong synergistic interaction between the Menin inhibitor MI-503 (Borkin et al., 2015) and (Bernt et al., 2011; Guenther et al., 2008) or divided into two classes, with 5 0 binding indicating a dependence on H3K79me2 (Garcia-Cuellar et al., 2016). Our results suggest that it is not the presence of MLL-AF4 and H3K79me2/3 that is most predictive of a dependence on H3K79me2, but the presence of MLL-AF4 spreading. Our observations also show that spreading strongly correlates with Menin and ENL binding and occurs across uCpG landscapes in the gene body that are within close proximity to the gene promoter. Unmethylated CpG regions in gene bodies typically display a relatively low CG density, which is possibly why we do not observe other CXXC proteins binding in the gene body. Therefore, spreading of MLL-FPs may be made possible by Menin/ENL-mediated stabilization at gene body uCpG regions where uCpG density is too low for a strong CXXC-uCpG interaction. Although wild-type MLL can also interact with Menin, a co-operation with fusion partner proteins such as ENL may generate complexes that permit MLL-FP dimerization (Mueller et al., 2007; Yokoyama et al., 2010) and through this mechanism create a spreading domain of MLL-FP that is anchored by CXXC-uCpG interactions in close proximity to each other, something that is unavailable to wildtype MLL.
It is unknown whether an ability to spread into the body of particular gene targets drives higher expression and initiates progression of leukemia or whether these gene targets are Figure S7 .
already highly expressed and the active chromatin landscape is simply a pre-requisite for facilitating spreading. Nevertheless, in the context of these remaining questions, our study has revealed that spreading of MLL-AF4 defines the expression of a subset of genes that are important for leukemia and are characterized by gene activation that is predictive of a poor prognosis. These target genes are particularly sensitive to DOT1L inhibition, which provides a new molecular rationale for the specificity of DOT1L or Menin inhibition in MLL-AF4 leukemias, and the possibility of combining this with drugs that target less sensitive spreading targets such as those that target BCL-2.
EXPERIMENTAL PROCEDURES
Cell Lines, Cultures, and Drug Treatment Studies Cell lines, culture methods, and drug treatment protocols used in this study are listed in Supplemental Experimental Procedures. CB was collected under the auspices of a National Research Ethics Service-approved study with written informed consent. Human fetal bone samples were obtained through the Human Development Biology Resource (http://www.hdbr.org).
Western Blot Analysis
Western blot analysis was performed as previously described (Wilkinson et al., 2013) . Antibodies used for western blot analysis are listed in Supplemental Experimental Procedures. 160, 80, 40, 20, 10 , and 5 nM, and DMSO control) alone, or in combination with a 1:10 ratio of either EPZ5676 (C), SGC0946 (D), or MI503 (E) (3,200, 1,600, 800, 400, 200, 100, and 50 nM, and DMSO control). (F) A tabular summary of the combination index for the different drug treatments calculated as in Milella et al. (2002) .
ChIP Assays and ChIP-Seq
ChIP and ChIP-seq experiments were performed as described in Supplemental Experimental Procedures and as previously described (Benito et al., 2015; Wilkinson et al., 2013) .
TetR Recruitment System
For the TetR recruitment assay, we used the previously engineered Tet-operon (TetO) mESC line (Blackledge et al., 2014) . MLL-AF4, Menin, and PAF1 cDNA were inserted downstream of the FS2-TetR coding sequence in the original pCAGFS2TetR vector, by ligation-independent cloning (LIC). Plasmids were transfected into TetO mESCs using Lipofectamine 2000, and clones stably expressing TetR fusions were selected using puromycin (1 mg/mL), or MLL-AF4 cDNA was transiently transfected into mESCs at 60%-70% confluency using Lipofectamine 2000. Cells were collected 24 hr after transfection.
Gene Targets and Spreading Peaks
ChIP-seq peaks were called as described in Supplemental Experimental Procedures. Gene targets were defined as any gene where the transcription start site (TSS) overlapped directly with a peak. A peak was classed as spreading if it overlapped the TSS of a gene and extended over 4 kb from the TSS into the gene body without going beyond the transcription end site (TES) of the gene. If a peak exhibited spreading at two different genes (or isoforms with different TSS co-ordinates), both spreading-gene pairs were kept. Nascent RNA-Seq Nascent RNA-seq and gene expression analysis was performed as described in Supplemental Experimental Procedures.
Survival Analysis
Clinical datasets and survival analyses are detailed in Supplemental Experimental Procedures.
Statistics
Data were analyzed using Fisher's exact test, Wilcoxon test, and Mann-Whitney U test, where appropriate. Results were deemed significant if p < 0.05. Unless otherwise indicated, data are shown as mean ± SD. This paper analyzed datasets from GEO: GSE13313, GSE28460, GSE29130, GSE34861, GSE73528, GSE74812, and GSE84116; and ArrayExpress: E-MTAB-3593 (for a detailed list of datasets, see Table S7 ).
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